The U.S. Food and Drug Administration (FDA) has granted clearance of CytomX and Amgen’s Investigational New Drug Application (IND) for CX-904, a T-cell-engaging bispecific antibody, to treat advanced solid tumors. Solid tumors can be malignant or benign, typically being classified as a sarcoma, lymphoma, or carcinoma. As a bispecific artificial protein, CX-904 will bind to the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 protein complex and T cell co-receptor, effectively directing T-cells against tumor antigens. Typical therapy options for solid tumors can include radiation, chemotherapy, and surgery. CytomX is a clinical-stage biopharmaceutical company that focusses on developing therapies to treat a range of life-threating cancers and is committed to addressing leading oncological challenges.

Read more here.